drugset / Trial / NCT00667420
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
A pilot study to determine the safety of using perioperative panitumumab with EOX (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus and stomach.
Timeline
- Start
- 2008-04
- Primary completion
- 2011-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab | Monoclonal antibody | 9 mg/kg | Intravenous |
| Background | Capecitabine | Small molecule | 400 mg/m2 | — |
| Background | Epirubicin | Small molecule | 50 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |